Communiqués GSK plc

Actions

GSK

GB00BN7SWP63

Temps réel estimé Cboe Europe Autres places de cotation 13:05:02 07/06/2024			Varia. 5j.	Varia. 1 janv.
1 619 ^GBX	-1,30 %		-8,39 %	+11,59 %

10:17	GSK : JP Morgan toujours vendeur	ZD
06/06	GSK conclut l'achat de la société américaine Elsie Biotechnologies pour un montant pouvant atteindre 50 millions de dollars	MT

Communiqués

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

GSK accelerates oligonucleotide platform and pipeline medicines with acquisition of Elsie Biotechnologies \| GSK	09:52	AQ
GSK : accelerates oligonucleotide platform and pipeline medicines with acquisition of Elsie Biotechnologies	06/06	PU
Jemperli (dostarlimab) trial continues to show unprecedented results with no evidence of disease in 100% of patients with locally advanced mismatch repair deficient (dMMR) rectal cancer \| GSK	04/06	AQ
GSK : Jemperli (dostarlimab) trial continues to show unprecedented results with no evidence of disease in 100% of patients with locally advanced mismatch repair deficient (dMMR) rectal cancer - Form 6-K	03/06	PU
Jemperli (dostarlimab-gxly) trial continues to show unprecedented results with no evidence of disease in 100% of patients with locally advanced mismatch repair deficient (dMMR) rectal cancer	03/06	BU
GSK : Jemperli (dostarlimab) trial continues to show unprecedented results with no evidence of disease in 100% of patients with locally advanced mismatch repair deficient (dMMR) rectal cancer	03/06	PU
GSK : Blenrep combination reduced the risk of disease progression or death by nearly 50% versus standard of care combination in relapsed/refractory multiple myeloma - Form 6-K	03/06	PU
Statement: Zantac (ranitidine) litigation - Delaware State Court Daubert Ruling - Form 6-K	03/06	PU
Statement: Zantac (ranitidine) litigation - Delaware State Court Daubert Ruling \| GSK	03/06	AQ
Blenrep combination reduced the risk of disease progression or death by nearly 50% versus standard of care combination in relapsed/refractory multiple myeloma \| GSK	03/06	AQ
GSK : Blenrep combination reduced the risk of disease progression or death by nearly 50% versus standard of care combination in relapsed/refractory multiple myeloma	02/06	PU
Belantamab Mafodotin combination reduced the risk of disease progression or death by nearly 50% versus standard of care combination in relapsed/refractory multiple myeloma	02/06	BU
New data at ASCO showcases the transformational potential of GSK's oncology portfolio \| GSK	29/05	AQ
Statement: Zantac (ranitidine) litigation - Valadez and Williams cases - Form 6-K	24/05	PU
New data at ASCO showcases the transformational potential of GSK's oncology portfolio \| GSK	24/05	AQ
Statement: Zantac (ranitidine) litigation - Valadez and Williams cases \| GSK	24/05	AQ
GSK : New data at ASCO showcases the transformational potential of GSK's oncology portfolio	23/05	PU
Statement: Zantac (ranitidine) litigation - Valadez and Williams cases	23/05	PU
GSK announces positive results from phase III severe asthma trials of depemokimab \| GSK	21/05	AQ
GSK : announces positive results from phase III severe asthma trials of depemokimab - Form 6-K	21/05	PU

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Filtres

A la une

GSK PLC : Les marchés effrayés créent une opportunité d'entrée pour GSK

Le 04 juin 2024 à 14:38

GSK plc : Reprend des couleurs

Le 03 mai 2024 à 11:03